DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Ritchlin C, Rahman P, Kavanaugh A. et al.
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ann Rheum Dis 2014;
73: 990-999
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.